Gilead Sciences Inc. - ENTERPRISE
Heidi Marchand. PharmD, RPh, Executive Director and Head of Global Regulatory Policy & Intelligence leads Gilead’s newly established leadership position to develop and implement strategies to shape and influence regulatory policy in selected areas of interest in the external regulatory environment in line with Gilead’s mission to advance innovative therapeutics and improve patient care.
Heidi joins Gilead from the U.S. FDA where she served for the last 11 years as Assistant Commissioner, Office of Health Affairs in the Office of the Commissioner. She represented U.S. FDA on high-profile and complex matters of new policies and programs that impact patients, patient advocacy, health professionals, consumers, state and federal organizations and regulated industry on implementation and adoption of innovative health technologies. Heidi has a deep understanding of operations within the U.S. FDA and developed complex strategic stakeholder interactions among FDA organizational centers including CDER, CBER and CDRH. Achievements during her tenure at U.S. FDA include supervision of an office of over 20 multi-disciplinary science and health professionals to evaluate stakeholders’ activities and respond to public health emerging and urgent issues across therapeutic areas (e.g. Opioid Risk and Mitigation Strategy, educational programs with the American Society of Clinical Oncology Association etc.).
Prior to joining the U.S. FDA, Heidi was Head of Global Regulatory Policy and Intelligence at both Amgen and Pfizer. In addition, she worked within Regulatory Affairs at Novartis and served for 6 years at FDA where she was Executive Secretary for the National Task Force on AIDS Drug Development, chartered by the Secretary of Health and Human Services to advise on AIDS drug development barriers. Heidi holds a Doctor of Pharmacy from the Medical College of Virginia and is a licensed pharmacist in Virginia and Florida.
Monday, September 14, 2020
2:05 PM – 3:00 PM EDT